A randomized, double-blind, placebo-controlled study of monoclonal Anti-IgE antibody Omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric population

被引：0
|
作者：
Mitra, B. [1 ]
机构：
[1] Base Hosp Delhi Cantt, Dept Pediat, New Delhi, India
来源：
EXPERIMENTAL DERMATOLOGY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-IGE ANTIBODY OMALIZUMAB IN THE MANAGEMENT OF PRURITUS IN CHRONIC SPONTANEOUS URTICARIA IN THE PEDIATRIC POPULATION
    Mitra, Barnali
    Vasudevan, Biju
    Solanki, Reema
    Mitra, Debdeep
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 1016 - 1017
  • [2] A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis
    Pinto, J. M.
    Mehta, N.
    DeTineo, M.
    Wang, J.
    Baroody, F. M.
    Naclerio, R. M.
    RHINOLOGY, 2010, 48 (03) : 318 - 324
  • [3] Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study
    Yacoub, Mona-Rita
    Ramirez, Giuseppe A.
    Berti, Alvise
    Mercurio, Giuseppe
    Breda, Daniela
    Saporiti, Nicoletta
    Burastero, Samuele
    Dagna, Lorenzo
    Colombo, Giselda
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2018, 176 (3-4) : 268 - 271
  • [4] Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study
    Metz, Martin
    Torene, Rebecca
    Kaiser, Sergio
    Beste, Michael T.
    Staubach, Petra
    Bauer, Andrea
    Brehler, Randolf
    Gericke, Janine
    Letzkus, Martin
    Hartmann, Nicole
    Erpenbeck, Veit J.
    Maurer, Marcus
    ALLERGY, 2019, 74 (01) : 141 - 151
  • [5] Omalizumab normalises levels of high affinity IgE receptor-positive skin cells in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study
    Metz, M.
    Staubach, P.
    Bauer, A.
    Brehler, R.
    Gericke, J.
    Kangas, M.
    Ashton-Chess, J.
    Jarvis, P.
    Pan, W.
    Georgiou, P.
    Canvin, J.
    Erpenbeck, V. J.
    Maurer, M.
    ALLERGY, 2014, 69 : 87 - 88
  • [6] Omalizumab normalizes gene expression in lesional skin of patients with chronic spontaneous urticaria: Results from a randomized, double-blind, placebo-controlled study
    Metz, Martin
    Torene, Rebecca
    Letzkus, Martin
    Hartmann, Nicole
    Staubach, Petra
    Bauer, Andrea
    Brehler, Randolf
    Ashton-Chess, Joanna
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB64 - AB64
  • [7] DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF KETOTIFEN IN CHRONIC URTICARIA
    PHANUPHAK, P
    LOCHARERNKUL, O
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1986, 77 (01) : 187 - 187
  • [8] Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients
    Jorg, L.
    Pecaric-Petkovic, T.
    Reichenbach, S.
    Coslovsky, M.
    Stalder, O.
    Pichler, W.
    Hausmann, O.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (02): : 196 - 204
  • [9] A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis
    Carter, Melody C.
    Maric, Irina
    Brittain, Erica H.
    Bai, Yun
    Lumbard, Keith
    Bolan, Hyejeong
    Cantave, Daly
    Scott, Linda M.
    Metcalfe, Dean D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 1004 - +
  • [10] Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study
    Nettis, E
    Colanardi, MC
    Barra, L
    Ferrannini, A
    Vacca, A
    Tursi, A
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (03) : 533 - 538
12345